DNA Methylation and Complex Human Disease
Edited by: Michel Neidhart, Center of Experimental Rheumatology, Center for Clinical Research, University Hospital Zurich, Switzerland
Description
DNA Methylation and Complex Human Disease reviews the possibilities of methyl-group-based epigenetic biomarkers of major diseases, tailored epigenetic therapies, and the future uses of high-throughput methylome technologies.
This volume includes many pertinent advances in disease-bearing research, including obesity, type II diabetes, schizophrenia, and autoimmunity. DNA methylation is also discussed as a plasma and serum test for non-invasive screening, diagnostic and prognostic tests, as compared to biopsy-driven gene expression analysis, factors which have led to the use of DNA methylation as a potential tool for determining cancer risk, and diagnosis between benign and malignant disease.
Therapies are at the heart of this volume and the possibilities of DNA demethylation. In cancer, unlike genetic mutations, DNA methylation and histone modifications are reversible and thus have shown great potential in the race for effective treatments. In addition, the authors present the importance of high-throughput methylome analysis, not only in cancer, but also in non-neoplastic diseases such as rheumatoid arthritis.
Key Features
- Discusses breaking biomarker research in major disease families of current health concern and research interest, including obesity, type II diabetes, schizophrenia, and autoimmunity
- Summarizes advances not only relevant to cancer, but also in non-neoplastic disease, currently an emerging field
- Describes wholly new concepts, including the linking of metabolic pathways with epigenetics
- Provides translational researchers with the knowledge of both basic research and clinic applications of DNA methylation in human diseases
Readership
Basic biology and translational researchers above graduate level interested in developmental biology, genetics, health genomics, epigenesis in complex disease, and therapeutic possibilities
Table of Contents
- DNA methylation – Introduction
- DNA methylation and epigenetics biomarkers in cancer
- DNA methylation and epigenetic biomarkers in non-neoplastic diseases
- DNA methylation and environmental factors
- DNA methylation and epidemiology
- DNA methylation and viral infections
- DNA methylation and cancer
- DNA methylation in breast and ovarian carcinoma
- DNA methylation in tumorous multi-drug resistance
- DNA methylation and endocrinology
- DNA methylation in metabolic diseases (obesity, type II diabetes)
- DNA methylation in pituitary diseases
- DNA methylation and development
- DNA methylation in growth retardation
- DNA methylation in cardiology
- DNA methylation and neurology
- DNA methylation in psychiatric diseases (schizophrenia, alcohol and drug abuses)
- DNA methylation in neurodegenerative diseases
- DNA methylation and autoimmunity
- DNA methylation in lymphocyte development
- DNA methylation in stem cell diseases
- DNA methylation and rheumatology – introduction
- DNA methylation in synovial fibroblasts
- DNA methylation in osteoporosis
- Epigenetic therapies
- Demethylation agents (5-azacytidine)
- Methyl donors (s-adenoyl methionine)
- Methylome analysis of complexe diseases
- Methylome analysis in cancer
- Methylome analysis in non-neoplastic disease
- Outlook
Available now at Store.Elsevier.com